Kura Oncology, Inc. $KURA Stock: Nan Fung Trinity HK Ltd. Trims Stake

Nan Fung Trinity HK Ltd. lessened its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 36.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,174,880 shares of the company’s stock after selling 667,470 shares during the quarter. Nan Fung Trinity HK Ltd.’s holdings in Kura Oncology were worth $12,583,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Pictet Asset Management Holding SA raised its stake in shares of Kura Oncology by 22.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 14,412 shares of the company’s stock worth $154,000 after purchasing an additional 2,656 shares during the period. Alps Advisors Inc. boosted its holdings in shares of Kura Oncology by 30.8% in the 3rd quarter. Alps Advisors Inc. now owns 117,876 shares of the company’s stock worth $1,262,000 after buying an additional 27,783 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kura Oncology in the 3rd quarter worth about $49,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Kura Oncology in the 3rd quarter worth about $228,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Kura Oncology by 14.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,232 shares of the company’s stock valued at $175,000 after buying an additional 2,104 shares during the period.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Teresa Bair sold 8,442 shares of the stock in a transaction on Monday, September 28th. The stock was sold at an average price of $10.50, for a total transaction of $88,641.00. Following the sale, the insider owned 187,002 shares in the company, valued at $1,963,521. This represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Brian Powl sold 15,430 shares of the stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total value of $165,872.50. Following the sale, the insider owned 136,819 shares in the company, valued at approximately $1,470,804.25. This represents a 10.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 153,881 shares of company stock worth $1,708,183. Company insiders own 7.60% of the company’s stock.

Kura Oncology Trading Down 3.9%

NASDAQ KURA opened at $7.43 on Friday. The company’s 50 day moving average is $10.28 and its 200-day moving average is $9.77. Kura Oncology, Inc. has a 12-month low of $6.75 and a 12-month high of $13.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.60 and a quick ratio of 4.71.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.04. The company had revenue of $22.84 million for the quarter, compared to analysts’ expectations of $24.94 million. Kura Oncology had a negative net margin of 369.26% and a negative return on equity of 336.24%. Equities research analysts predict that Kura Oncology, Inc. will post -3.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on KURA. UBS Group set a $24.00 price objective on shares of Kura Oncology in a report on Thursday. Citizens Jmp reiterated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research note on Monday, August 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, October 14th. Barclays set a $24.00 target price on shares of Kura Oncology in a research report on Wednesday, October 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, October 15th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.88.

Kura Oncology Profile

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.